

East African Medical Journal Vol. 88 No. 12 December 2011

MYCOBACTERIUM TUBERCULOSIS GENETIC DIVERSITY AND DRUG RESISTANCE CONFERRING MUTATIONS IN THE DEMOCRATIC REPUBLIC OF THE CONGO

L. Fenner, Institute of Social and Preventive Medicine, University of Bern, Switzerland, S. Gagneux, Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland, G. Kabuya, National TB Control Programme, Kinshasa, Democratic Republic of the Congo, D. Stucki, Swiss Tropical and Public Health Institute, J. P. Kabuayi, National TB Control Programme, Kinshasa, Democratic Republic of the Congo, S. Borrell, Swiss Tropical and Public Health Institute, R. Frei, Clinical Microbiology Laboratory, University Hospital Basel, Switzerland, C. Burri, Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland, D. Kalemwa, Swiss Tropical and Public Health Institute, Kinshasa office, Kinshasa, Democratic Republic of the Congo, M. Egger, Institute of Social and Preventive Medicine, University of Bern, Switzerland and J. P. Okiata, National TB Control Programme, Kinshasa, Democratic Republic of the Congo

Request for reprints to: Dr. L. Fenner, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland

MYCOBACTERIUM TUBERCULOSIS GENETIC DIVERSITY AND DRUG RESISTANCE CONFERRING MUTATIONS IN THE DEMOCRATIC REPUBLIC OF THE CONGO

L. FENNER, S. GAGNEUX, G. KABUYA, D. STUCKI, J. P. KABUAYI, S. BORRELL, R. FREI, C. BURRI, D. KALEMWA, M. EGGER and J. P. OKIATA

ABSTRACT

Background: The Democratic Republic of the Congo (DRC) belongs to the 22 tuberculosis (TB) high-burden countries and to the 27 high-burden multidrug-resistant (MDR)-TB countries. To date, there are no data on the genetic diversity of *Mycobacterium tuberculosis* in the DRC.

Objective: To describe the genetic diversity and the distribution of drug resistance conferring mutations of clinical *M. tuberculosis* isolates from the DRC.

Design: We analysed consecutive *M. tuberculosis* single patient isolates cultured in 2010 at the laboratory of the National TB Control Programme in Kinshasa.

Setting: National TB Control Programme in Kinshasa, DRC.

Results: Isolates from 50 patients with pulmonary TB were analysed, including 45 patients (90%) who failed treatment. All isolates belonged to the Euro-American lineage (main phylogenetic Lineage 4). Six different spoligotype families were observed within this lineage, including LAM (20 patients, 40%), T (15 patients; 30%), U (4 patients; 8%), S (3 patients; 6%), Haarlem (2 patients; 4%), and X (1 patient; 2%). No *M. africanum* strains were observed. The most frequently detected drug resistance-conferring mutations were *rpoB* S531L and *katG* S315T1. Various other mutations, including previously unreported mutations, were detected.

Conclusions: The Euro-American lineage dominates in the DRC, with substantial variation in spoligotype families. This study fills an important gap on the molecular map of *M. tuberculosis* in sub-Saharan Africa.

INTRODUCTION

The Democratic Republic of the Congo (DRC) has an estimated population of 63 million and a gross national income per capita of 280 US\$. The DRC is one of 22 tuberculosis (TB) high-burden countries with an estimated incidence of 392 new TB cases per 100,000 per year (1). The country also belongs to the 27 countries with a high burden of multidrug-resistant (MDR) TB, the prevalence of MDR among new cases is 2.3% (2).

Mycobacterium tuberculosis complex (MTBC) has a global phylogeographic population structure

consisting of six main phylogenetic lineages (3): Lineage 1 (known as Indo-Oceanic lineage), Lineage 2 (known as East-Asian lineage), Lineage 3 (known as Delhi/CAS), Lineage 4 (known as Euro-American lineage), and Lineages 5/6 (known as West African lineages 1 and 2 also known as *M. africanum*). These bacterial lineages are associated with specific geographic regions and human populations (3-5). Lineage 4 represents the *M. tuberculosis* family with the largest geographical spread and includes spoligotype strain families such as "Haarlem (H)" or "Latin-American-Mediterranean (LAM)". There is increasing evidence that strain diversity in

M. tuberculosis plays a role in the presentation of disease in humans (3,6) and in animal models (7). For example, a study from West Africa found a lineage-dependent rate of progression from infection to active disease comparing *M. africanum* versus *M. tuberculosis* (8). A study from Vietnam showed that a higher proportion of adults with pulmonary TB caused by Lineage 4 (Euro-American lineage) had a consolidation on the chest X-ray radiographs, and that TB meningitis caused by Lineage 2 (East-Asian lineage) was associated with disease progression and leukocyte count in cerebrospinal fluid (9). Another study from Vietnam found that Lineage 4 strains were less likely to cause TB meningitis compared to other lineages (10). Furthermore, *M. tuberculosis* strains belonging to Lineage 2 (which includes the Beijing genotype) are associated with drug resistance and infection with the human immunodeficiency virus (HIV) (7, 11, 12), and have been rapidly emerging in some areas, for example in Cape Town, South Africa (11, 13), or in the Canary Islands in Spain (14). Finally, recent studies have reported associations between *M. tuberculosis* lineages and specific human genetic polymorphisms in genes associated with the immune system (10, 15). Taken together, *M. tuberculosis* is more genetically diverse than previously thought (16) and this genetic diversity may translate into phenotypic effects.

To date, there are no data on the genetic diversity of *M. tuberculosis* or on the distribution of drug resistance conferring mutations in the DRC. Therefore, we characterised clinical *M. tuberculosis* isolates to gain insights into the genetic population structure of *M. tuberculosis* and the frequency of drug resistance conferring mutations in the DRC.

MATERIALS AND METHODS

Study setting: We analysed consecutive *M. tuberculosis* single patient isolates cultured in 2010 at the laboratory of the National TB Control Programme in Kinshasa. Cultures were mainly done in patients failing treatment and when (multi) drug resistance was suspected. The National TB Control Programme in DRC runs TB testing and treatment centres throughout Kinshasa and other parts of the country. Its TB laboratory in Kinshasa acts as the reference laboratory for the country following international guidelines (17). Clinical data were obtained from the National TB Control Programme.

Strain culturing and DNA extraction: Clinical specimens were processed and strains cultured on Löwenstein-

Jensen medium according to international guidelines (17) at the TB reference laboratory in Kinshasa. Standard phenotypic drug susceptibility testing (DST) for isoniazid and rifampicin were performed by proportion method according to international guidelines (17).

Molecular investigations: DNA was extracted from subcultures according to standard laboratory procedures. Mutations in *katG*, *inhA*, and *rpoB*, which are known to confer resistance to isoniazid and rifampicin, respectively, were determined using the GenoType MTBDRplus line probe assay (Hain Lifescience, Germany; *katG*, *inhA*, *rpoB* genes); and complemented by PCR amplification and direct sequencing of PCR products as described previously (18,19). Determination of the main *M. tuberculosis* lineages was performed by single nucleotide polymorphisms (SNPs) using multiplex real-time PCR with fluorescence-labelled probes (Taqman, Applied Biosystems, USA) as described before (20). The SNP used to define Lineage 4 was originally described by Sreevatsan *et al.* (21) and shown to be specific to this lineage (20). *M. tuberculosis* isolates were further genotyped by spoligotyping as previously described (22). Spoligo-International-Type (SIT) numbers were assigned using data published in the fourth international spoligotyping database (SpolDB4) (22). Spoligotype families were used to define sub-lineages within the main *M. tuberculosis* lineages (23).


Ethical approval: The study was approved by the Ethics Committee of the Kinshasa School of Public Health in Kinshasa, DRC. No informed consent was required by the Ethics Committee. All data and strains were collected in the context of routine care and no additional data collection or contact with patients occurred for this study. The data were completely de-identified before analysis using unique study numbers.

RESULTS

Patient characteristics: A total of 50 pulmonary TB patients were included. Median age was 28 years (interquartile range 26-34 years), 33 (66%) were male, four (8%) were known to be HIV-infected (Table 1). Treatment failure was the most frequent TB category (45 patients; 90%), and the patients were primarily from the capital Kinshasa (33 patients; 66%) and from Lubumbashi (9 patients; 18%). Figure 1 shows the geographical origin of the 50 isolates.

Figure 1

Origin of the clinical *Mycobacterium tuberculosis* isolates in the Democratic Republic of the Congo (shaded in grey)

**Table 1**

Clinical characteristics of the 50 tuberculosis (TB) patients from the Democratic Republic of Congo included in the study

Characteristic	Value
Age, median (interquartile range), years	28(26-34)
Sex, n (%)	
Male	33(66)
Female	17(34)
HIV status, n (%)	
HIV-positive	4(8)
Not determined	46(92)
TB categories, n (%)	
Treatment failure	45(90)
New case	3(6)
Previous TB	1(2)
Recurrent case	1(2)
Origin of patients, n (%)	
Kinshasa	33(66)
Lubumbashi	9(18)
Kisangani	3(6)
Kananga	2(4)
Other regions (Bunia, Goma, Kamina)	3(6)

Genetic diversity of M. tuberculosis: The molecular analyses showed that all isolates belonged to Lineage 4 (Euro-American lineage). Considerable genetic diversity was, however, observed within this lineage based on spoligotyping. The most frequent spoligotype family was the LAM (Latin-American-Mediterranean) family (20 isolates; 40%) and the T-family (the "ill-defined" family; 15 isolates; 30%), followed by the S, U, H and X families (Table 2). One strain belonged to the Cameroon family

("LAM10_CAM"), and two strains to the Zimbabwe family ("LAM11_ZWE") (Table 3). Table 3 details the spoligotyping results according to the classification of SpolDB4, using the SITVIT molecular database, which is available at <http://www.pasteur-guadeloupe.fr:8081/SITVITDemo/index.jsp>. Spoligotypes are patterns formed by the presence or absence of 43 spacers in the DR locus of *Mycobacterium tuberculosis* and these patterns (Table 3).

Table 2
Molecular data of the 50 clinical Mycobacterium tuberculosis isolates

Characteristic	n(%)	
	All n=50	MDR n=28
Spoligotyping families, n (%)		
LAM (Latin-American-Mediterranean)	20(40.0)	14(50.0)
T (ill-defined "lineage")	15(30.0)	5(17.8)
U	4(8.0)	3(10.7)
S	3(6.0)	3(10.7)
H	2(4.0)	1(3.6)
X	1(2.0)	1(3.6)
Undesignated	5(10.0)	1(3.6)
Main <i>M. tuberculosis</i> lineages, n (%)		
Lineage 4 (Euro-American lineage)	50(100)	28(100)
Other lineages	0	0
Drug resistance mutations, n (%)		
rpoB (codon)		
S531L	21(42.0)	17(60.7)
D516V	6(12.0)	4(14.3)
S522Q	3(6.0)	2(7.1)
N518S ¹ /L533P	1(2.0)	1(3.6)
H526H ²	1(2.0)	1(3.6)
H526N	1(2.0)	0
H526D	1(2.0)	0
S531W	1(2.0)	1(3.6)
P535S	1(2.0)	0
Deletion Q-F-M (513-515) ¹	1(2.0)	0
katG (codon)		
S315T1 (AGC>ACC)	31(62.0)	24(85.7)
L333R ¹	2(4.0)	2(7.1)
S315N	2(4.0)	0
M377R ¹	1(2.0)	1(3.6)
inhA Promote		
C15T	4(8.0)	2(7.1)
T8C	1(2.0)	1(3.6)

MDR, multidrug-resistant as determined by phenotypic drug susceptibility testing

¹first described in this study

²synonymous mutation

is the major group of *M. tuberculosis* strains in the neighbouring countries of Chad (26) and Cameroon (27,28) does not seem to occur very frequently in the DRC. *M. africanum* lineages have not been detected in the DRC, Angola (29) or Chad (26). However, *M. africanum* was found to be declining in Cameroon in the last three decades, and the same may be true for DRC.

Despite major improvements in treatment and control, TB remains a major public health problem worldwide, particularly in the context of MDR and extensively drug-resistant (XDR) TB (2,30). Drug susceptibility can be tested by culture methods based on bacterial growth, or alternatively by molecular methods detecting drug resistance-associated gene mutations (31). Antibiotic resistance mutations are usually associated with a fitness cost and recent studies suggest that the genetic background in *M. tuberculosis* strains can influence the relative fitness (32-34). Interestingly, *M. tuberculosis* strains with low- or no-cost resistance mutations (e.g. *rpoB* S531L) are also the most frequent among clinical isolates (33). In our study, we found that *rpoB* S531L and *katG* S315T1 were the most frequent drug resistance-conferring mutations in the DRC. We also detected new mutations that have never been reported before, such as *rpoB* mutations N518S, the *rpoB* deletion 513-515, *katG* mutation L333R and *katG* mutation M377R. *rpoB* L533P associated with low-level rifampicin resistance (35) was present in one strain together with *rpoB* mutation N518S. Such low-level drug resistance mutations are difficult to detect using liquid culture based drug resistance testing (35,36). The frequency of these low-level drug resistance mutations in the DRC and the significance of the mutations discovered in this study will need to be evaluated in larger studies.

Our study has several limitations. We could not exclude with certainty that other lineages and less common spoligotyping families or resistance mutations existed due to the relatively small sample size. Secondly, we stress that the strains analysed among selected TB patients failing treatment mainly in Kinshasa did not reflect the *M. tuberculosis* strains causing the disease in the country at large, but will be representative of those sent to the reference laboratory and cultured.

In conclusion, the Euro-American lineage dominates in the DRC, with substantial variation in spoligotype families. To our knowledge, this is the first study on the genetic diversity of *M. tuberculosis* in the DRC, mainly in Kinshasa, one of the largest cities in sub-Saharan Africa which is of great interest due to the high TB and MDR TB burden (1,2). In-depth knowledge of the population biology and epidemiology of *M. tuberculosis* is essential for the development of new TB diagnostics, drugs, and vaccines (3,37,38). Future studies on the molecular epidemiology of TB in DRC, with a special focus on MDR and HIV-infected populations, will provide a more complete picture of the distribution of *M. tuberculosis* genetic diversity in this part of the world.

ACKNOWLEDGEMENTS

To the Congolese patients whose data and strains were

used in this study, the staff at the Congolese National TB Programme and at the local representation of the Swiss Tropical and Public Health Institute in Kinshasa for local study coordination. We are grateful to Vladimira Hinic at the University Hospital of Basel for technical assistance. We also would like to thank Robert W. Ryder and Godfrey Woelk from the International epidemiological Databases to Evaluate AIDS (IeDEA) in Central Africa for their support and helpful discussions.

FUNDING

The study has been supported by internal funds from the Institute of Social and Preventive Medicine, University of Bern, Switzerland. LF and ME were supported by IeDEA Southern Africa (National Institute of Allergy and Infectious Diseases grant no. 5U01-AI069924-5). SG, DS and SB were supported by the Swiss National Science Foundation (grant no. PP00A-119205) and by the National Institutes of Health (grant no. R01AI090928-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

REFERENCES

1. World Health Organization. Global TB database. Country profile: Democratic Republic of Congo. Available at http://apps.who.int/globalatlas/predefinedreports/tb/PDF_Files/cod.pdf. Accessed August 2009. World Health Organization 2008.
2. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth global report. World Health Organisation, Geneva 2008.
3. Gagneux, S. and Small, P. M. Global phylogeography of *Mycobacterium tuberculosis* and implications for tuberculosis product development. *Lancet Infect. Dis.* 2007; **7**: 328-337.
4. Baker, L., Brown, T., Maiden, M. C., and Drobniewski, F. Silent nucleotide polymorphisms and a phylogeny for *Mycobacterium tuberculosis*. *Emerg. Infect. Dis.* 2004; **10**: 1568-1577.
5. Hirsh, A. E., Tsolaki, A. G., DeRiemer, K., et al. Stable association between strains of *Mycobacterium tuberculosis* and their human host populations. *Proc. Natl. Acad. Sci. U S A* 2004; **101**: 4871-4876.
6. Malik, A. N. and Godfrey-Faussett, P. Effects of genetic variability of *Mycobacterium tuberculosis* strains on the presentation of disease. *Lancet Infect. Dis.* 2005; **5**: 174-183.
7. Coscolla, M. and Gagneux, S. Does *Mycobacterium tuberculosis* genomic diversity explain disease diversity? *Drug Discov. Today Dis. Mech.* 2010; **7**: e43-e59.
8. de Jong, B. C., Hill, P. C., Aiken, A., et al. Progression to active tuberculosis, but not transmission, varies by *Mycobacterium tuberculosis* lineage in the Gambia. *J Infect Dis.* 2008 Aug 14.
9. Thwaites, G., Caws, M., Chau, T. T., D'Sa, A., Lan, N. T., Huyen, M. N., et al. Relationship between *Mycobacterium tuberculosis* genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. *J. Clin. Microbiol.* 2008; **46**: 1363-1368.

10. Caws, M., Thwaites, G., Dunstan, S., Hawn, T. R., Lan, N. T., Thuong, N. T., *et al.* The influence of host and bacterial genotype on the development of disseminated disease with *Mycobacterium tuberculosis*. *PLoS Pathog.* 2008; **4**: e1000034.
11. Middelkoop, K., Bekker, L. G., Mathema, B., Shashkina, E., Kurepina, N., Whitelaw, A., *et al.* Molecular Epidemiology of *Mycobacterium tuberculosis* in a South African Community with High HIV Prevalence. *J. Infect. Dis.* 2009; **200**: 1207-1211.
12. Caws, M., Thwaites, G., Stepniewska, K., *et al.* Beijing genotype of *Mycobacterium tuberculosis* is significantly associated with human immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. *J. Clin. Microbiol.* 2006; **44**: 3934-3939.
13. Cowley, D., Govender, D., February, B., *et al.* Recent and rapid emergence of W-Beijing strains of *Mycobacterium tuberculosis* in Cape Town, South Africa. *Clin. Infect. Dis.* 2008; **47**: 1252-1259.
14. Caminero, J. A., Pena, M. J., Campos-Herrero, M. I., *et al.* Epidemiological evidence of the spread of a *Mycobacterium tuberculosis* strain of the Beijing genotype on Gran Canaria island. *Am. J. Respir. Crit. Care. Med.* 2001; **164**: 1165-1170.
15. van Crevel, R., Parwati, I., Sahiratmadja, E., *et al.* Infection with *Mycobacterium tuberculosis* Beijing genotype strains is associated with polymorphisms in *SLC11A1/NRAMP1* in Indonesian patients with tuberculosis. *J. Infect. Dis.* 2009; **200**: 1671-1674.
16. Hershberg, R., Lipatov, M., Small, P. M., *et al.* High functional diversity in *Mycobacterium tuberculosis* driven by genetic drift and human demography. *PLoS Biol* 2008 Dec 16; **6**: e311.
17. Rieder, H. L., Van Deun, A., Kam, K. M., *et al.* Priorities for tuberculosis bacteriology services in low-income countries. Second edition. Paris: International Union Against Tuberculosis and Lung Disease, 2007. *IUTLD* 2007.
18. Gagneux, S., Burgos, M. V., DeRiemer, K., *et al.* Impact of bacterial genetics on the transmission of isoniazid-resistant *Mycobacterium tuberculosis*. *PLoS Pathog* 2006; **2**: e61.
19. Feuerriegel, S., Cox, H. S., Zarkua, N., *et al.* Sequence analyses of just four genes to detect extensively drug-resistant *Mycobacterium tuberculosis* strains in multidrug-resistant tuberculosis patients undergoing treatment. *Antimicrob Agents Chemother* 2009; **53**: 3353-3356.
20. Gagneux, S., DeRiemer, K., Van, T., *et al.* Variable host-pathogen compatibility in *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. U S A* 2006; **103**: 2869-2873.
21. Sreevatsan, S., Pan, X., Stockbauer, K. E., *et al.* Restricted structural gene polymorphism in the *Mycobacterium tuberculosis* complex indicates evolutionarily recent global dissemination. *Proc. Natl. Acad. Sci. U S A* 1997 **2**; **94**: 9869-9874.
22. Brudey, K., Driscoll, J. R., Rigouts, L., *et al.* *Mycobacterium tuberculosis* complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. *BMC Microbiol.* 2006; **6**: 23.
23. Kato-Maeda, M., Gagneux, S., Flores, L., *et al.* Strain classification of *Mycobacterium tuberculosis*: congruence between large sequence polymorphisms and spoligotypes. *Intl. J. Tuberc. and Lung Dis.* 2011; **15**: 131-133.
24. Victor, T. C., de Haas, P. E., Jordaan, A. M., *et al.* Molecular characteristics and global spread of *Mycobacterium tuberculosis* with a Western Cape F11 genotype. *J. Clin. Microbiol.* 2004; **42**: 769-772.
25. Chihota, V., Apers, L., Mungofa, S., Kasongo, W., *et al.* Predominance of a single genotype of *Mycobacterium tuberculosis* in regions of Southern Africa. *Int. J. Tuberc. Lung Dis.* 2007; **11**: 311-318.
26. Diguimbaye, C., Hilty, M., Ngandolo, R., *et al.* Molecular characterization and drug resistance testing of *Mycobacterium tuberculosis* isolates from Chad. *J. Clin. Microbiol.* 2006; **44**: 1575-1577.
27. Niobe-Eyangoh, S. N., Kuaban, C., Sorlin, P., *et al.* Genetic biodiversity of *Mycobacterium tuberculosis* complex strains from patients with pulmonary tuberculosis in Cameroon. *J. Clin. Microbiol.* 2003; **41**: 2547-2553.
28. Niobe-Eyangoh, S. N., Kuaban, C., Sorlin, P., *et al.* Molecular characteristics of strains of the cameroon family, the major group of *Mycobacterium tuberculosis* in a country with a high prevalence of tuberculosis. *J. Clin. Microbiol.* 2004; **42**: 5029-5035.
29. de Jong, B. C., Antonio, M., Gagneux, S. *Mycobacterium africanum*--review of an important cause of human tuberculosis in West Africa. *PLoS Negl. Trop. Dis.* 2010; **4**: e744.
30. Gandhi, N. R., Nunn, P., Dheda, K., *et al.* Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. *Lancet* 2010; **375**: 1830-43.
31. Ramaswamy, S. and Musser, J. M. Molecular genetic basis of antimicrobial agent resistance in *Mycobacterium tuberculosis*: 1998 update. *Tuberc. Lung Dis.* 1998; **79**: 3-29.
32. Borrell, S. and Gagneux, S. Infectiousness, reproductive fitness and evolution of drug-resistant *Mycobacterium tuberculosis*. *Int. J. Tuberc. Lung Dis.* 2009; **13**: 1-11.
33. Gagneux, S., Long, C. D., Small, P. M., *et al.* The competitive cost of antibiotic resistance in *Mycobacterium tuberculosis*. *Science* 2006; **312**: 1944-1946.
34. Gagneux, S. Fitness cost of drug resistance in *Mycobacterium tuberculosis*. *Clin. Microbiol. Infect.* 2009; **1**: 66-68.
35. Van, D. A., Barrera, L., Bastian, I., *et al.* *Mycobacterium tuberculosis* strains with highly discordant rifampin susceptibility test results. *J. Clin. Microbiol.* 2009; **47**: 3501-3506.
36. Van, D. A., Wright, A., Zignol, M., *et al.* Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. *Int. J. Tuberc. Lung Dis.* 2011; **15**: 116-124.
37. Fauci, A. S. Multidrug-resistant and extensively drug-resistant tuberculosis: The National Institute of Allergy and Infectious Diseases research agenda and recommendations for priority research. *J. Infect. Dis.* 2008; **197**: 1493-1498.
38. Fenner, L., Egger, M. and Gagneux, S. Annie Darwin's death, the evolution of tuberculosis and the need for systems epidemiology. *Int. J. Epidemiol.* 2009; **38**: 1425-1428.